Development of Novel Combinatorial Treatment Strategies to Overcome Resistance in Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Development of Novel Combinatorial Treatment Strategies to Overcome Resistance in Breast Cancer PDF full book. Access full book title Development of Novel Combinatorial Treatment Strategies to Overcome Resistance in Breast Cancer by Prajakta Shirish Oak. Download full books in PDF and EPUB format.
Author: Prajakta Shirish Oak
Publisher:
ISBN:
Category :
Languages : en
Pages : 204
Get Book Here
Book Description
Author: Prajakta Shirish Oak
Publisher:
ISBN:
Category :
Languages : en
Pages : 204
Get Book Here
Book Description
Author: Zodwa Dlamini
Publisher: Springer Nature
ISBN: 3031528603
Category :
Languages : en
Pages : 390
Get Book Here
Book Description
Author: Sameer Ullah Khan
Publisher: Springer Nature
ISBN: 9819716667
Category :
Languages : en
Pages : 392
Get Book Here
Book Description
Author: Francesco Sabbatino
Publisher: LAP Lambert Academic Publishing
ISBN: 9783659672057
Category :
Languages : en
Pages : 148
Get Book Here
Book Description
The resistance to anticancer drugs (cytotoxic compounds and molecular targeted agents) and radiotherapy is the main obstacle for an effective treatment of human cancers. This limitation to the success of cancer treatment has led to the study of the molecular mechanisms underling drug resistance as well as to the development of novel combinatorial strategies which can overcome the acquired and intrinsic resistance. In this book by presenting novel mechanisms of drug resistance two different lines of research are analyzed: a) The molecular basis of resistance to the treatment with the novel inhibitors of the tyrosine-kinase encoded by the mutated form of the gene BRAF in melanoma carrying the mutant BRAF V600E and potential therapeutic strategies to counteract this resistance. b) The role of specific inhibition of PARP1 enzyme to potentiate the cytotoxicity of chemo-radiotherapy in human glioblastoma cells. The analysis of the presented results should help to shed some light on this timely and clinically relevant topic, and should be especially useful to students as well as medical doctors, or anyone else who may be interest in cancer research or treatment.
Author: Yan Cheng
Publisher: Frontiers Media SA
ISBN: 2832541844
Category : Medical
Languages : en
Pages : 198
Get Book Here
Book Description
Basic scientific background Breast cancer is one of the most common cancer and the most frequent cause of cancer death among women worldwide. Currently, subtyping breast cancers into hormone receptor (HR) positive, human epidermal growth factor receptor-2 overexpressing (HER2+), and triple negative breast cancer (TNBC) is the basis of diagnosing and treating this disease. The main treatment strategies for breast cancer include surgery, endocrine therapy, molecular targeted therapy, chemotherapy, radiotherapy, immunotherapy and gene therapy. However, resistance of breast cancer cells to chemotherapeutic agents, molecular targeted therapies and immunotherapy may occur either intrinsically or de nova, and is often ultimately responsible for treatment failure. Therefore, drug resistance poses a major challenge to breast cancer treatment. Current developments: Drug resistance in breast cancer is a complex clinical condition originating from a wide range of molecular alterations. The development of endocrine therapy resistance is believed to be associated with many cellular changes, such as ESR1 gene mutations, bypassing estrogen signaling pathway and altered tamoxifen metabolism. Meanwhile, changes in immune response, alternation of drug-binding property and downstream pathways are involved in the mechanisms of drug resistance in HER2+ breast cancer. In addition, resistance to chemotherapeutic agents predominantly arises from increased drug efflux and cross resistance. Current studies suggest that treatment strategies and therapeutics have to be designed specifically to each patient in different clinical situations. The use of modern genomic, proteomic and functional analytical techniques has contributed to identify novel genes and signaling networks involved in breast cancer drug resistance. Moreover, the use of high-throughput techniques in combination with bioinformatics and systems biology approaches has aided the interrogation of clinical samples and allowed the identification of molecular signatures and genotypes that predict responses to certain drugs. Despite much progress has been made in the field of breast cancer drug resistance, such as combination therapy and drug-loaded nanoparticles, the complexity and variability of drug resistance mechanism still inevitably lead to the continuous occurrence of drug resistance. Therefore, with the increasing amounts of anti-breast cancer agents, there are now unprecedented opportunities to understand and overcome drug resistance through further research into mechanisms and corresponding strategies, which will help achieve lasting disease control and bring survival benefits to patients with advanced cancer. Papers of interest: The current Research Topic of Frontiers in Pharmacology focuses on publishing Original Research, Review articles and Case Reports focusing on (a) elucidating mechanisms of drug resistance in breast cancer, target mutations, tumor microenvironment, undiscovered genes and signaling pathways; (b) promising drug delivery systems that can enhance the sensitivity of anti- breast cancer agents to various tumors; (c) strategies that can improve patient care during bio-chemotherapeutic treatments; (d) small molecule compounds that are effective against drug-resistant breast tumors (e) biomarkers of chemotherapy resistance in breast cancer patients and (f) in vitro and in vivo models. Guidelines for article of submission: - Authors must stick to the set guidelines for ethical practices by the Frontiers journals. - The main content of the article must have certain innovation and research significance. - The authors should describe the construction method of drug-resistant cell lines when using them for experiments in the article.
Author: Rishabha Malviya
Publisher: John Wiley & Sons
ISBN: 1394209843
Category : Medical
Languages : en
Pages : 228
Get Book Here
Book Description
MULTI-DRUG RESISTANCE IN CANCER The book details the mechanisms underlying multi-drug cellular resistance and the targets of novel chemotherapeutic agents. Cancer is a major killer all over the world. Even with all the progress made, chemotherapy is still the mainstay of modern cancer treatment. The progression of the cellular defeat of numerous independent anticancer drugs in terms of their chemical structure is a major barrier to successful chemotherapy. Multi-drug resistance (MDR) is a term for the fact that most cancer patients exhibit this phenomenon. According to the numbers, drug resistance carries the blame for 90% of cancer patient deaths. Refractory cancer and tumor recurrence are common outcomes of prolonged chemotherapy. Because of the prevalence of drug-resistance mutations, the difficulty of treating tumors increases and the therapeutic efficacy of drugs decreases. Multi-Drug Resistance in Cancer: Mechanism and Treatment Strategies contains nine chapters that cover topics such as: studying the mechanics of resistance to drugs by autophagy; studies to delineate the role of efflux transporters; expression of drug transporters; resistance to targeted therapies in breast cancer; advances in metallodrug driven combination treatment for cancer; and use of natural agents for the overcoming of cancer drug resistance. The book aims to provide the latest data on the mechanisms of cellular resistance to anticancer agents currently used in clinical treatment. It provides a better understanding of the mechanisms of MDR and targets of novel chemotherapy agents which should guide future research concerning new effective strategies in cancer treatment. Audience This book is written for pharmaceutical and biomedical scientists and researchers at both the bench and in the clinic who are interested in the mechanisms and strategies for overcoming cancer’s multi-drug resistance.
Author: Stephen Hiscox
Publisher: Springer Science & Business Media
ISBN: 1402085265
Category : Medical
Languages : en
Pages : 202
Get Book Here
Book Description
One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens. Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.
Author: Jun Zhou
Publisher: Humana Press
ISBN: 9781617796647
Category : Medical
Languages : en
Pages : 492
Get Book Here
Book Description
Chemotherapy is one of the major treatment options for cancer patients; however, the efficacy of chemotherapeutic management of cancer is severely limited by multidrug resistance, in that cancer cells become simultaneously resistant to many structurally and mechanistically unrelated drugs. In the past three decades, a number of mechanisms by which cancer cells acquire multidrug resistance have been discovered. In addition, the development of agents or strategies to overcome resistance has been the subject of intense study. This book contains comprehensive and up-to-date reviews of multidrug resistance mechanisms, from over-expression of ATP-binding cassette drug transporters such as P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance p- tein to the drug ratio-dependent antagonism and the paradigm of cancer stem cells. The book also includes strategies to overcome multidrug resistance, from the development of compounds that inhibit drug transporter function to the modulation of transporter expression. In addition, this book contains techniques for the detection and imaging of drug transporters, methods for the investigation of drug resistance in animal models, and strategies to evaluate the efficacy of resistance reversal agents. The book intends to provide a state-of-the-art collection of reviews and methods for both basic and clinician investigators who are interested in cancer multidrug resistance mechanisms and reversal strategies. Tianjin, China Jun Zhou v Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix 1 Multidrug Resistance in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Bruce C. Baguley 2 Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets . . . . . . . . . . . . . . . . . . . . . . . . . .
Author: John A. Katzenellenbogen
Publisher:
ISBN:
Category :
Languages : en
Pages : 23
Get Book Here
Book Description
We have conceived of an approach to prepare by combinatorial methods, libraries of novel ligands for the estrogen receptor, that might be useful in the treatment or prevention of breast cancer, by the creation of simple amide or five-membered ring heterocyclic core structures that display peripheral substituents (phenols, aliphatic groups, etc.) commonly found in non-steroidal estrogens. We have made good progress on the preparation of novel estrogen of the diphenyl carboxamide class, the diphenylsulfonamide class, the phenyl benzylcarboxamide and sulfonamide classes, and the pyrazole, oxazole, thiazole, and imidazole classes. Members of same class have high affinity for the estrogen receptor. Future efforts will be directed at perfecting the solid phase synthesis of the pyrazole class, which appear to be the most promising, and expanding the size of the libraries that can b% prepared.
Author: Prashant Kesharwani
Publisher: Elsevier
ISBN: 0443132100
Category : Computers
Languages : en
Pages : 460
Get Book Here
Book Description
Cancer Epigenetics, Guns and Triggers: Targeting the Right Player via Nanotechnology Approach is a complete package that provides a comprehensive and thorough understanding of the key players that modulate the various steps of carcinogenesis and malignant progression of the disease and the critical targets to be exploited for developing novel modalities of diagnosis and therapeutics. Since epigenetic aberrations can be potentially reversed and restored to their normal state through epigenetic therapy, the book also discusses the challenges and the future of the field with the cutting-edge revelations and limitations that this research endeavor can offer, thereby helping the readers to enhance their critical thinking and adopt strategies of therapeutic importance. • Delivers a detailed and complete journey of how cancer develops, its genetics, as well as other internal and external factors that are contributors of carcinogenesis • Provides in-depth knowledge on epigenetics and the various epigenetic biomolecules, enzymes, and other signaling pathways that are promising entities for drug discovery and chemotherapeutics • Presents state-of-the-art information on the next-generation cancer therapies, challenges, and future of the field
